Endoret®(PRGF®) Technology in Ophthalmology

The Endoret® (prgf®) technology represents a new milestone in the development and use of autologous biological therapies for tissue repair and regeneration.

Over more than 15 years, it has been possible to verify the safety and therapeutic potential of the different Endoret® (prgf®) formulations in different areas of medicine. A knowledge, a safety and an effectiveness that now reach the field of ophthalmology. The set of Endoret® (prgf®) technology formulations represents a solution in terms of safety, effectiveness and reproducibility that ophthalmologists demanded in the treatment of various eye diseases.

The process of obtaining the Endoret® (prgf®) is simple and easily reproducible.

Endoret® (prgf®) Ophthalmology Kits

Endoret® (prgf®) Eye Drop Kit

New generation of autologous eye drops within your grasp.


  • Fast and simple to prepare, no diluting required
  • It accelerates tissue regeneration thanks to its high concentration of growth factors that encourage cellular proliferation and migration
  • High antifibrotic potential that encourages corneal transparency and protects against corneal scarring and leucomas
  • Daily treatment with no need to store in the fridge as it can be used any time, anywhere


  • Moderate to Severe Dry Eye
  • Persistent Epithelial Defects
  • Corrective Amyotrophia Surgery
  • Burns, perforations, inflammation

Endoret® (prgf®) Surgery Kit

Customised eye surgery offering maximum versatility to adapt the surgery to each patient

1 Single protocol, 4 Formulations

Fibrine membrane
suturable autologous, strong, easy to handle and completely resorbable

Liquid plasma and Clot
enriched with Growth Factors

Eye drops
that maintain the growth factor supply after surgery

For further information about Endoret® (PRGF®) Kits, see related documentation.


  • Autologous
    Taken from the patient's blood, so there are no side effects.
  • Optimum concentration of platelets
    An appropriate concentration of platelets that promote greater cellular proliferation.
  • Patented activation
    Allows controlled release of growth factors.
  • Leukocyte free formulation
    Endoret® does not contain leukocytes. Including leukocytes increases pain and inflammation and accelerates fibrin deterioration.
  • No dilutions or preservatives
    Same pH and osmolarity as tears for greater regenerative potential and bio-safety.
  • Reduces fibrosis
    Greater antifibrotic potential compared to SA.
  • Reproducible
    Protocol is strictly defined and tested for the preparation process and clinical application.
  • Versatile
    Different therapeutic formulations obtained in the same process help adapt the product to clinical needs.

Safety and Guarantees

  • Stability guarantee
    Endoret eye drops® ( PRGF®) remain stable for 3 months when frozen and 72 hours at room temperature, maintaining biological and biosafety potential intact.
  • Regulatory guarantees
    Endoret® ( PRGF®) has obtained the CE marking for use and sales in ophthalmology.

    The ENDORET® system meets all regulatory requirements as a closed technique, according to the standard from the Spanish Agency for Medicine and Healthcare Products dated 23rd May 2013, establishing the classification for non substitutive therapeutic use of autologous plasma and its parts, components or derivatives, as medicine for human use.
  • Efficiency guarantees
    BTI has large-scale worldwide clinical support published in this field, upholding its effectiveness with more than 175 international scientific publications.
  • Additional guarantees
    BTI certifies its customers' specific training to use this technology.

    BTI also guarantees traceability for its materials, and helps you provide your patients with all the necessary information.

Do you want more information? Contact us through the following form.

 I need more information


Are you interested in contacting us?